Published in Bone Res on June 28, 2013
Function of matrix IGF-1 in coupling bone resorption and formation. J Mol Med (Berl) (2013) 0.90
Decreased osteogenesis of adult mesenchymal stem cells by reactive oxygen species under cyclic stretch: a possible mechanism of age related osteoporosis. Bone Res (2015) 0.82
Halofuginone attenuates osteoarthritis by inhibition of TGF-β activity and H-type vessel formation in subchondral bone. Ann Rheum Dis (2015) 0.79
Differential effects of IGF-1 deficiency during the life span on structural and biomechanical properties in the tibia of aged mice. Age (Dordr) (2016) 0.76
Enoxaparin and rivaroxaban have different effects on human mesenchymal stromal cells in the early stages of bone healing. Bone Joint Res (2016) 0.76
The effects of interleukin-1β in modulating osteoclast-conditioned medium's influence on gelatinases in chondrocytes through mitogen-activated protein kinases. Int J Oral Sci (2015) 0.75
miR-23a/b regulates the balance between osteoblast and adipocyte differentiation in bone marrow mesenchymal stem cells. Bone Res (2016) 0.75
DNA N(6)-methyladenine demethylase ALKBH1 enhances osteogenic differentiation of human MSCs. Bone Res (2016) 0.75
Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts. Curr Osteoporos Rep (2016) 0.75
Cell migration: integrating signals from front to back. Science (2003) 29.13
Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28
Bone resorption by osteoclasts. Science (2000) 11.68
Endogenous bone marrow MSCs are dynamic, fate-restricted participants in bone maintenance and regeneration. Cell Stem Cell (2012) 4.67
TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med (2009) 4.58
Osteoblast-specific knockout of the insulin-like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chem (2002) 4.52
Skeletal remodeling in health and disease. Nat Med (2007) 4.31
Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev (2009) 3.53
In vivo clonal analysis reveals self-renewing and multipotent adult neural stem cell characteristics. Cell (2011) 3.47
Matrix IGF-1 maintains bone mass by activation of mTOR in mesenchymal stem cells. Nat Med (2012) 3.34
Nestin expression--a property of multi-lineage progenitor cells? Cell Mol Life Sci (2004) 3.26
Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev (2008) 2.64
Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med (2011) 2.00
Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone (2009) 1.94
Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology (2000) 1.93
The role of liver-derived insulin-like growth factor-I. Endocr Rev (2009) 1.87
Inhibition of Sca-1-positive skeletal stem cell recruitment by alendronate blunts the anabolic effects of parathyroid hormone on bone remodeling. Cell Stem Cell (2010) 1.60
The fate of circulating osteoblasts. N Engl J Med (2005) 1.36
Molecular mechanisms in coupling of bone formation to resorption. Crit Rev Eukaryot Gene Expr (2009) 1.34
Insulin-like growth factor 1 enhances the migratory capacity of mesenchymal stem cells. Biochem Biophys Res Commun (2007) 1.34
Bone remodelling. Br J Orthod (1998) 1.24
High serum IGFBP-2 is predictive of increased bone turnover in aging men and women. J Bone Miner Res (2007) 1.21
IGF-I secreted by osteoblasts acts as a potent chemotactic factor for osteoblasts. Bone (2008) 1.07
IGF-1 as an early marker for low bone mass or osteoporosis in premenopausal and postmenopausal women. J Bone Miner Metab (2008) 1.01
Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res (2011) 1.01
Osteoporosis prevention starts in adolescence. J Am Acad Nurse Pract (2004) 0.94
Serum levels of insulin-like growth factor (IGF); IGF-binding proteins-3, -4, and -5; and their relationships to bone mineral density and the risk of vertebral fractures in postmenopausal women. Calcif Tissue Int (2006) 0.93
Concentration of insulin-like growth factor (IGF)-I and -II in iliac crest bone matrix from pre- and postmenopausal women: relationship to age, menopause, bone turnover, bone volume, and circulating IGFs. J Clin Endocrinol Metab (1998) 0.92
Clinical relevance of systemic and local IGF-I. Endocr Dev (2005) 0.91
GH and IGF-I as therapeutic agents for osteoporosis. J Endocrinol Invest (2005) 0.91
How to manage osteoporosis in children. Best Pract Res Clin Rheumatol (2005) 0.89
Differential patterns of nestin and glial fibrillary acidic protein expression in mouse hippocampus during postnatal development. J Vet Sci (2011) 0.86
Blunting type 1 insulin-like growth factor receptor expression exacerbates neuronal apoptosis following hypoxic/ischemic injury. BMC Neurosci (2011) 0.83
Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab (1996) 0.80